PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
45.23%
EBIT growth of 45.23% while Biotechnology median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
45.56%
Operating income growth of 45.56% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand.
30.89%
Net income growth of 30.89% while Biotechnology median is zero. Walter Schloss might see potential if moderate gains can keep rising.
30.77%
EPS growth of 30.77% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
30.77%
Diluted EPS growth of 30.77% while Biotechnology median is zero. Walter Schloss might see a slight edge that could improve over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
98.49%
OCF growth of 98.49% while Biotechnology is zero. Walter Schloss might see a modest positive difference, which can compound over time.
98.49%
FCF growth of 98.49% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
94.54%
OCF/share CAGR of 94.54% while Biotechnology median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
94.54%
OCF/share CAGR of 94.54% while Biotechnology median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
94.54%
3Y OCF/share growth of 94.54% while Biotechnology median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-8.80%
Negative 10Y net income/share CAGR vs. Biotechnology median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
-8.80%
Negative 5Y CAGR while Biotechnology median is 0.00%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-8.80%
Negative 3Y CAGR while Biotechnology median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
-273.39%
Negative 10Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman would see a firm-specific weakness if peers still expand equity.
-273.39%
Negative 5Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-273.39%
Negative 3Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.09%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-4.63%
Negative BV/share change while Biotechnology median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
0.22%
Debt growth of 0.22% while Biotechnology median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
-43.90%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.